USANA Health Sciences (NYSE:USNA) Rating Increased to Hold at Zacks Investment Research

Posted by on Jun 9th, 2022

USANA Health Sciences (NYSE:USNA – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday, Zacks.com reports.

According to Zacks, “USANA Health Sciences Inc. develops and manufactures high-quality nutritional, personal care and weight management products. The company’s three primary product lines consist of nutritional, personal care and weight management products. The company’s products are distributed primarily through a network marketing system. “

A number of other brokerages have also recently issued reports on USNA. TheStreet cut shares of USANA Health Sciences from a “b” rating to a “c+” rating in a research report on Wednesday, February 9th. DA Davidson lowered their price target on shares of USANA Health Sciences from $86.00 to $76.00 in a research report on Wednesday, April 27th. Finally, StockNews.com lowered shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 26th. Two research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $105.00.

Shares of USANA Health Sciences stock opened at $72.79 on Thursday. The firm has a market cap of $1.40 billion, a PE ratio of 13.45 and a beta of 0.84. USANA Health Sciences has a 12-month low of $67.01 and a 12-month high of $104.76. The company’s fifty day simple moving average is $75.35 and its two-hundred day simple moving average is $87.31.

USANA Health Sciences (NYSE:USNA – Get Rating) last announced its quarterly earnings results on Tuesday, April 26th. The company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. USANA Health Sciences had a net margin of 9.41% and a return on equity of 27.04%. The business had revenue of $272.87 million for the quarter, compared to analyst estimates of $270.80 million. During the same quarter last year, the firm earned $1.45 EPS. As a group, sell-side analysts expect that USANA Health Sciences will post 5.28 earnings per share for the current year.

A number of institutional investors have recently added to or reduced their stakes in the stock. Altshuler Shaham Ltd lifted its position in shares of USANA Health Sciences by 28.3% during the third quarter. Altshuler Shaham Ltd now owns 508 shares of the company’s stock valued at $47,000 after buying an additional 112 shares during the last quarter. Cornercap Investment Counsel Inc. raised its position in shares of USANA Health Sciences by 0.9% in the 3rd quarter. Cornercap Investment Counsel Inc. now owns 14,346 shares of the company’s stock valued at $1,323,000 after purchasing an additional 126 shares during the last quarter. Gladius Capital Management LP raised its position in shares of USANA Health Sciences by 20.2% in the 1st quarter. Gladius Capital Management LP now owns 905 shares of the company’s stock valued at $72,000 after purchasing an additional 152 shares during the last quarter. Vident Investment Advisory LLC raised its position in shares of USANA Health Sciences by 3.0% in the 4th quarter. Vident Investment Advisory LLC now owns 7,690 shares of the company’s stock valued at $779,000 after purchasing an additional 225 shares during the last quarter. Finally, Meritage Portfolio Management raised its position in shares of USANA Health Sciences by 11.4% in the 1st quarter. Meritage Portfolio Management now owns 2,523 shares of the company’s stock valued at $200,000 after purchasing an additional 258 shares during the last quarter. 55.72% of the stock is currently owned by institutional investors.

USANA Health Sciences Company Profile (Get Rating)

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products.

Further Reading

Get a free copy of the Zacks research report on USANA Health Sciences (USNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Want More Great Investing Ideas?

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.